greeksoup/ stock research
Stock research / United States / DXCM · Surgical & Medical Instruments & Apparatus · Nasdaq

Dexcom Inc. (DXCM)

Dexcom is a medical device company focused on continuous glucose monitoring systems, used to manage diabetes and metabolic health by patients, their caregivers and clinicians. It received approval from the Food and Drug Administration and commercialised its first product in 2006. At the end of 2025 it had approximately 11,100 employees globally, including 11,000 full-time.

Dexcom Inc.

Dexcom is a medical device company focused on continuous glucose monitoring systems, used to manage diabetes and metabolic health by patients, their caregivers and clinicians. It received approval from the Food and Drug Administration and commercialised its first product in 2006. At the end of 2025 it had approximately 11,100 employees globally, including 11,000 full-time.

What a Dexcom system does

A sensor sits on the body and reads glucose continuously, replacing the finger stick. The key technologies are biomaterials, membrane systems, electrochemistry and low power microelectronics. The membrane is built from multiple polymer layers configured to let through the right mix of glucose and oxygen, which react with a glucose-specific enzyme to create an extremely low electrical current measured in pico-amperes; that current is then translated into a glucose value. The electronics are packaged in a small, sealed, lightweight unit.

A transmitter sends the reading wirelessly to a Dexcom receiver or to a compatible mobile phone, where an app displays real-time and trended values and raises alerts and alarms. With the current systems the receiver's functions can be had through an iOS or Android device instead, though some jurisdictions, the United States among them, may require a receiver as the primary display or a backup. Readings arrive every five minutes, and no finger stick is needed for calibration or for treatment decisions unless symptoms do not match the readings.

The product line

G7 is the current generation, cleared in the United States for everyone with diabetes aged two and over. It received a CE Mark in March 2022 and marketing authorisation from the Food and Drug Administration in December 2022 through the 510(k) process, and is an integrated continuous glucose monitoring system classified as a Class II device. G7 15 Day, authorised in April 2025 for people over 18 in the United States, extends the wear period to 15.5 days. The company reports a mean absolute relative difference of 8.0% for G7 15 Day, with 94.2% of values within 20% of their comparator, and describes it as the most accurate such system cleared by the Food and Drug Administration.

G6, authorised in March 2018, was the first continuous glucose monitor the regulator permitted to work as part of an integrated system with other compatible devices such as automated insulin delivery systems and insulin pumps. The filing states that the company anticipates transitioning its G6 customers to the G7 and G7 15 Day sensor systems by the end of 2026. Dexcom ONE+, CE marked in November 2023 and launched in several European countries, carries many of the same features as G7 and covers people aged two and over including pregnant women; the earlier Dexcom ONE is anticipated to be phased out by the end of 2026.

Stelo, launched in August 2024, is different in kind: a biosensor for adults with prediabetes and Type 2 diabetes who do not use insulin, and the first over-the-counter glucose biosensor in the United States. Because it needs no prescription, it reaches beyond people with diabetes to those managing metabolic health.

Around the sensors sit Dexcom Share and Dexcom Follow, which send a patient's glucose information to the cloud and on to apps belonging to up to ten designated followers, who can monitor remotely and receive alerts, including on a wearable device. The Dexcom Real-Time API, cleared in July 2021, lets authorised third-party developers pull real-time data into their own digital health apps for permitted uses, though not for automated insulin delivery or for settings the system is not cleared for, such as hospital inpatient care.

Partnerships and manufacturing

The company has multiple collaboration agreements that integrate its monitoring with insulin delivery: a partner's pump or pen receives and displays glucose readings from the transmitter and, in some cases, uses them for semi-automated insulin delivery. It also collaborates with organisations running Type 2 diabetes treatment programmes, and, since Stelo, with consumer technology companies that want to offer metabolic health insights.

Manufacturing is primarily at Mesa, Arizona and Penang, Malaysia, with a new facility being built at Athenry, Ireland. Production has to happen in a highly controlled and clean environment to keep out particles and other contaminants that limit yield and quality. In March 2025 the company received a warning letter from the Food and Drug Administration following inspections of its San Diego, California and Mesa facilities relating to observed non-conformities in manufacturing. Selling runs through a direct field sales force, supplemented by distribution arrangements in North America and several international markets.

From Dexcom's annual report on Form 10-K for the year ended 31 December 2025. The filing

Compare with another name What $10,000 in Dexcom became

Latest results

Latest quarterQ3 FY2026ended 30 September 2026 · 10-Q filed 29 October 2026
Revenue
$1.3 billion
+11.2% on the year · +2.8% on the quarter
Q4 FY2024Q3 FY2026
Net income
$275 million
-3.1% on the year · +10.4% on the quarter
Q4 FY2024Q3 FY2026
Diluted EPS
$0.72
+2.9% on the year · +12.5% on the quarter
Q4 FY2024Q3 FY2026

this quarterthe same quarter a year earlierHover a bar for its figure.

Read the Q3 FY2026 results →the 10-Q on EDGAR ↗
Last full yearFY2025ended 31 December 2025 · 10-K filed 12 February 2026
Revenue
$4.7 billion
+15.6% on the year
FY2018FY2025
Net income
$836 million
+45.1% on the year
FY2018FY2025
Diluted EPS
$2.09
+47.2% on the year
FY2018FY2025

this yearthe year beforeHover a bar for its figure.

The years before, in wordsDexcom (DXCM) reported revenue of $4.7 billion for fiscal 2025, the year ended 31 December 2025, up 15.6% on the year before. Net income was $836 million and diluted earnings per share $2.09. Revenue was $4.0 billion in fiscal 2024, $3.6 billion in fiscal 2023, $2.9 billion in fiscal 2022 and $2.4 billion in fiscal 2021. Net income in the same years was $576 million, $542 million, $341 million and $217 million. Over the twelve months to 30 September 2026, Dexcom reported revenue of $5.1 billion and net income of $991 million. Revenue grew 19.3% a year, compounded, over the five years to fiscal 2025. Dexcom had 373 million shares outstanding at the latest filed count. At 30 September 2026 it carried $1.2 billion of debt and $961 million of cash. At the close of 6 November 2026 the market cap of Dexcom was $29.6 billion, 31.1 times its earnings over the last twelve months.
Read the FY2025 results →the 10-K on EDGAR ↗

Ratios

From the filings

ROE39.1%
ROCE32.4%
Operating margin24.0%
Net margin19.4%
FCF margin21.5%
Interest cover91.3x
Debt to equity0.49x
Cash conversion1.43x
Share count, last 12 months-4.4%
Sales CAGR, 3 years17.0%
Profit CAGR, 3 years34.8%
EPS, TTM$2.55

At the close of 6 November 2026

Price$79.41
Market cap$29.6 billion
Stock P/E31.1x
Price to book11.7x
EV / EBITDA19.9x
Dividend yieldn/a
Market cap / sales5.8x
52-week high$92.34
52-week low$54.84
Price, 1 year36.9%
Price CAGR, 3 years-5.9%
Price CAGR, 5 years-13.0%

29 ready-made ratios, from FCF yield to net debt to EBITDA, wait on the Formulas page, each with what it tells you. Browse and add them →

Worked from the filed figures; hover a name for the formula.
Read moreThe priced ones use the latest price, the last regular-hours trade on IEX. Debt to equity here stands on the borrowing lines of Dexcom Inc.'s balance sheet, added together, finance leases inside them only where the company puts them there; operating leases are a separate line. Nothing here is a valuation or a view.
DXCMgreeksoup.ai
Daily prices to 6 November 2026, adjusted for splits; from 28 September 2026 each day's price is the last regular-hours trade on IEX.
Read moreData provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use. Day by day for the last three years; before that one point a week, carrying the week's last close and its average daily volume, so a volume bar means the same thing across the whole series; the bars sit under the price on their own scale, on the right. The moving averages need consecutive days and are drawn from the daily part. P/E is the close over the trailing four quarters' EPS as filed at each filing date, on the current share count; the dashed line is the median over the range shown. Sales and margin are quarterly revenue and the operating margin from the tables above. EV/EBITDA, price to book and market cap to sales use the latest filed balance sheet and share count at each date. Before the quarters on file begin, P/E, price to book and market cap to sales stand on each annual report from the day it was filed. Drawn in your browser; the range and overlay you pick are remembered here only.

Quarterly results

Q4 FY2021 * †Q1 FY2022 †Q2 FY2022Q3 FY2022Q4 FY2022 *Q1 FY2023 †Q2 FY2023 †Q3 FY2023 †Q4 FY2023 * †Q1 FY2024Q2 FY2024Q3 FY2024Q4 FY2024 *Q1 FY2025Q2 FY2025Q3 FY2025Q4 FY2025 *Q1 FY2026Q2 FY2026Q3 FY2026
Revenue6986296967708157428719751,0349211,0049941,1141,0361,1571,2091,2601,1921,3081,344
Cost of revenue226231247275274279325352378359378400458447468478467442478480
Gross profit473398450494541463546623657562627594656589689731793750830864
Gross margin68%63%65%64%66%62%63%64%63%61%62%60%59%57%60%60%63%63%63%64%
R&D150136122110116119119131136142136135140145148158148145153162
SG&A237219249235296296299286304319333306327310328331322350359376
Operating income0.641.377.014812547.2128206217101158152189134213242323255318327
Operating margin0%7%11%19%15%6%15%21%21%11%16%15%17%13%18%20%26%21%24%24%
Interest expense25.24.64.74.64.74.65.94.94.94.64.84.74.94.74.74.74.23.13.03.1
Pre-tax income-14.736.175.314613364.5159240246132188177211154241352341270318335
Tax raten/a-170%32%31%31%25%27%50%-4%-10%24%24%28%32%25%19%22%26%22%18%
Net income-19.497.350.910191.848.6116121256146144135152105180284267200249275
Net margin-3%15%7%13%11%7%13%12%25%16%14%14%14%10%16%23%21%17%19%20%
Diluted EPS-$0.20$0.93$0.12$0.24$0.22$0.12$0.28$0.29$0.62$0.36$0.35$0.34$0.38$0.27$0.45$0.70$0.68$0.51$0.64$0.72
Operating cash flow10671.0173293132155190269134209279200301184303660294526269326
Capital expenditure80.210291.510863.574.759.050.452.556.966.111112587.094.180.510276.684.752.9
Free cash flow25.6-30.681.318569.080.713121981.115221388.317796.8209579192449184273
Buybacksn/an/an/a558n/an/an/a0.0n/an/an/a750n/an/an/a187n/an/an/a400
Shares outstanding97m98m393m386m386m388m386m386m385m396m401m391m391m392m392m390m385m386m377m373m
Filing10-K10-Q10-Q10-Q10-K10-Q10-Q10-Q10-K10-Q10-Q10-Q10-K10-Q10-Q10-Q10-K10-Q10-Q10-Q
Each quarter as filed, linked to its filing.
Read more* The fourth quarter is the full year less the first three quarters, because the company files the year and not the quarter on its own. A fourth quarter's EPS, and its diluted share count where shown, are from the company's results press release for that quarter, checked against the company's filed figures or a second data source. A quarter marked † is shown as the company last restated it in a later filing, so it compares with the quarters around it on one basis; rest on a figure for the one first filed. EPS is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and the share count are as they are. Free cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Cash flow lines filed year to date are the difference between two filings. Shares outstanding are at the period end where the balance sheet tags them, otherwise the count on the filing's cover page. A derived fourth-quarter EPS is left blank when a split in the year makes the arithmetic meaningless.

Income statement (profit and loss)

FY2009 †FY2010 †FY2011 †FY2012 †FY2013FY2014FY2015FY2016FY2017FY2018FY2019FY2020 †FY2021 †FY2022 †FY2023FY2024FY2025TTM
Revenue29.748.676.399.91602594025737181,0321,4761,9272,4482,9103,6224,0334,6625,104
Cost of revenue26.030.240.453.359.982.91241952263685446477681,0271,3331,5951,8601,867
Gross profit3.718.435.846.61001762783784926649321,2801,6801,8832,2892,4382,8023,237
Gross margin12.3%37.8%47.0%46.6%62.6%68.0%69.3%66.0%68.5%64.4%63.1%66.4%68.6%64.7%63.2%60.5%60.1%63.4%
Research and development14.323.229.638.344.869.4138156185200274360517484506552599608
Selling, general and administrative35.240.551.164.084.21281982863494335166188101,0081,1851,2861,2911,406
Operating income-45.8-45.3-44.8-55.7-28.9-21.5-57.1-63.9-42.5-1861423002663915986009121,224
Operating margin-154.4%-93.1%-58.8%-55.8%-18.1%-8.3%-14.2%-11.1%-5.9%-18.1%9.6%15.5%10.9%13.4%16.5%14.9%19.6%24.0%
Interest expense8.01.50.00.20.90.80.40.712.822.760.317.718.818.620.319.018.313.4
Pre-tax incomen/a-55.2-44.7-55.8-29.8-22.3-57.5-64.9-48.6-1261042982573917107091,0881,262
Income taxn/a0.00.0-1.30.00.10.10.71.60.63.1-25239.949.6169133252271
Effective tax raten/an/an/an/an/an/an/an/an/an/a3.0%-84.5%15.5%12.7%23.8%18.7%23.2%21.5%
Net income-53.5-55.2-44.7-54.5-29.8-22.4-57.6-65.6-50.2-127101550217341542576836991
Net margin-180.3%-113.4%-58.7%-54.6%-18.6%-8.6%-14.3%-11.4%-7.0%-12.3%6.8%28.5%8.9%11.7%14.9%14.3%17.9%19.4%
Diluted EPS-$1.21-$0.97-$0.68-$0.79-$0.42-$0.30-$0.72-$0.78-$0.58-$1.44$1.10$1.33$0.53$0.82$1.30$1.42$2.09$2.55
Filing10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K
From each year's 10-K, linked; TTM is the last four quarters.
Read moreFree cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are. † The year as the company last restated it in a later filing; rest on a figure for the one first filed. EPS is as filed.

Revenue by region FY2014 to FY2025

FY2014FY2015FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025Share
of the parts, latest year
United States2243474985968181,1621,5101,8492,1422,6252,8903,33571.5%
International35.054.675.81222133144175997689971,1431,32728.5%
United StatesInternational
402FY2015718FY20171,476FY20192,448FY20213,622FY20234,662FY2025

$ million; hover a block for its figure and share

From the company's 10-Ks, in its own words (latest 10-K).
Read moreEach year's figures come from the most recent 10-K that includes that year. A year is shown only where the parts add up to the revenue above. Fiscal years are labelled by the year they end in.

First forecast against the result

Dexcom's sales growth landed at or above the top of the range in 2 and under it in 1 of the 3 years shown (FY2021 to FY2024).

+7.0FY2021+4.0FY2023−9.0FY2024
  • At or above the top of the range
  • Inside the range
  • Under the range

Each bar is the year's result against the top of its first forecast range, in percentage points. Hover a bar for the figures.

Fiscal yearFirst forecast
sales growth		Result
FY202115% to 20% reported27%
FY202315% to 20% reported24%
FY202416% to 21% organic12%
FY2026 forecast
Sales growth 11% to 13%, given 12 January 2026. Its result comes with the fourth-quarter results for FY2026.
First forecast
The full-year range the company gave with its fourth-quarter results for the year before, before any later change to it.
Result
The figure the company reported for that year with its next fourth-quarter results.
Years left out
Where the forecast or the result could not be read with confidence. Each figure in the table links to the results release it comes from.

Cash flow

FY2009 †FY2010 †FY2011 †FY2012 †FY2013FY2014FY2015FY2016FY2017FY2018FY2019FY2020 †FY2021 †FY2022 †FY2023FY2024FY2025TTM
Operating cash flow-39.4-42.7-30.1-33.12.423.649.056.292.01233144764426707489901,4411,414
Capital expenditure3.06.98.09.57.916.233.355.766.067.1180199389365237359364316
Free cash flow-42.4-49.6-38.1-42.6-5.57.415.70.526.056.113427753.33055126311,0771,098
Free cash flow margin-142.7%-101.9%-50.0%-42.6%-3.4%2.9%3.9%0.1%3.6%5.4%9.1%14.4%2.2%10.5%14.1%15.6%23.1%21.5%
Cash from investing-14.1-25.6-46.428.420.9-16.8-51.5-55.9-144-140-1,015-1,018-216-522-507-208536261
Cash from financing44.469.674.210.211.821.816.88.139971010.791210.4-552-319-735-1,686-2,546
Depreciation and amortisation2.42.43.86.67.08.410.815.016.129.148.767.1102156186218252275
Share-based compensation8.49.413.518.424.650.082.7111106102103119113126151170160154
Buybacksn/an/an/an/an/an/an/a0.00.01000.00.00.0558689750500n/a
Diluted shares, weightedn/an/an/an/an/an/an/an/a86m88m92m420m429m428m426m413m406m384m
Shares outstanding at period endn/a62m68m70m72m77m82m85m87m90m92m96m97m386m385m391m385m373m
Filing10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K
Cash paid in the year, from the cash flow statement.
Read moreThe dividend per share is as declared. Diluted shares are the weighted average for the year; a falling count is the buybacks net of issuance. TTM sums the last four quarters; the share counts are the latest quarter's.

Balance sheet

FY2009 †FY2010 †FY2011 †FY2012 †FY2013FY2014FY2015FY2016FY2017FY2018FY2019FY2020 †FY2021 †FY2022 †FY2023FY2024FY2025TTM
Funded by
Shareholders' equity-18.461.010477.084.11402212844196638831,5522,0422,1322,0692,1032,7462,535
Non-controlling interestn/an/an/an/an/an/an/an/an/an/an/a275n/an/an/an/an/an/a
Debtn/a0.50.07.06.84.62.30.03281,0101,0601,6671,9821,9702,4342,4411,2411,244
Operating lease liabilitiesn/an/an/an/an/an/an/an/an/a0.072.410298.694.680.165.073.477.5
Finance lease liabilitiesn/an/an/an/an/an/an/an/an/an/a14.454.057.059.658.658.553.851.0
Other liabilitiesn/a15.616.022.031.639.868.51191572423666417541,1351,6231,8172,2262,331
Total liabilities and equityn/a77.21201061221852924039041,9162,3954,2904,9335,3926,2646,4846,3406,239
Owned
Fixed assetsn/a10.815.018.920.731.254.71091461833215158021,056n/an/an/an/a
Goodwilln/an/a0.03.23.23.23.711.312.118.718.619.326.525.725.222.824.224.0
Intangible assetsn/an/a0.04.23.62.72.20.2n/an/an/an/a31.517313410370.889.4
Investmentsn/a42.279.440.611.411.829.135.1122107n/an/a1,6811,8292,1981,849218218
Securities held for sale or to maturityn/an/an/an/an/an/an/an/an/an/a1,0871,890n/an/an/an/an/an/a
Cash and equivalents3.64.92.68.143.271.886.194.54421,1374468181,053642566606918961
Receivablesn/an/an/an/an/a42.474.11021342272864285147139741,0061,2161,186
Inventoryn/a8.18.27.49.016.035.245.445.270.7120235357307560543629771
Other assetsn/a11.215.323.631.45.56.95.23.91731163854696461,8062,3553,2642,990
Total assetsn/a77.21201061221852924039041,9162,3954,2904,9335,3926,2646,4846,3406,239
Filing10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K
At the fiscal year end; the TTM column is the latest quarter end.
Read moreBoth totals are the company's own. Other liabilities is the filed total less the rows above it: payables, deferred revenue, taxes, borrowings the rows above do not carry and the rest; other assets is the same on the other side. Investments add the current and non-current lines as filed. Debt is the company's own stated total where it files one, otherwise its long-term debt with the current maturities, never parts added together. A row is left blank in a year where the lines shown overlap and the remainder would fall below nil.

Compounded growth

10 years5 years3 yearsTTM
Sales growth, compounded27.8%19.3%17.0%13.0%
Profit growth, compoundedn/a8.8%34.8%37.5%
Return on equity, average10.3%22.1%28.0%30.5%
Yearly growth, compounded; TTM is the last four quarters against the four before.
Read moreReturn on equity is net income over shareholders' equity at each year end, averaged over the window (the TTM column is the latest year alone); equity is the parent's shareholders' equity as tagged in the 10-K. Arithmetic on filed numbers, nothing forecast.

Questions

What was Dexcom's revenue in fiscal 2025?

Dexcom (DXCM) reported revenue of $4.7 billion for fiscal 2025, the year ended 31 December 2025, up 15.6% on the year before.

How much did Dexcom earn in fiscal 2025?

Net income was $836 million for fiscal 2025, and diluted earnings per share $2.09.

What is Dexcom's P/E ratio?

At the close of 6 November 2026, Dexcom traded at 31.1 times its earnings over the twelve months to 30 September 2026.

What is Dexcom's market cap?

The market cap of Dexcom was $29.6 billion at the close of 6 November 2026.

How much debt does Dexcom have?

At 30 September 2026 Dexcom carried $1.2 billion of debt and $961 million of cash.

Peers: Medical Equipment

CompanyMarket capP/EROEOp. marginSales growth
TTM		Debt to equityDiv. yield
Stryker Corp. SYK$124.0 billion34.7015.4%20.7%7.9%0.641.1%
3M Co. MMM$95.7 billion27.6185.7%18.8%1.7%3.631.7%
Boston Scientific Corp. BSX$62.0 billion18.1113.7%18.7%8.9%0.47n/a
Becton Dickinson & Co. BDX$57.7 billion63.803.9%9.6%-2.6%0.692.0%
Medline Inc. MDLN$52.2 billion57.614.9%5.7%n/a1.07n/a
Resmed Inc. RMD$33.1 billion21.4226.8%33.0%9.0%0.071.0%
Dexcom Inc. DXCM$29.6 billion31.1439.1%24.0%13.0%0.49n/a
West Pharmaceutical Services Inc. WST$27.9 billion44.8721.5%23.0%12.6%0.070.2%
Solventum Corp. SOLV$15.4 billion101.513.2%5.6%-2.8%1.05n/a
Baxter International Inc. BAX$13.3 billionn/a-11.1%-1.9%5.3%1.322.0%
Glaukos Corp. GKOS$13.3 billionn/a-23.7%-25.5%46.9%0.00n/a
Penumbra Inc. PEN$12.6 billion80.459.9%12.1%17.0%0.00n/a
All 110 in Medical Equipment
CompanyMarket capP/EROEOp. marginSales growth
TTM		Debt to equityDiv. yield
Intuitive Surgical Inc. ISRG$156.9 billion54.7518.5%28.4%20.5%0.00n/a
Medtronic plc MDT$130.3 billion25.0710.4%18.1%9.8%0.562.8%
Stryker Corp. SYK$124.0 billion34.7015.4%20.7%7.9%0.641.1%
3M Co. MMM$95.7 billion27.6185.7%18.8%1.7%3.631.7%
Boston Scientific Corp. BSX$62.0 billion18.1113.7%18.7%8.9%0.47n/a
Edwards Lifesciences Corp. EW$58.8 billion57.679.4%21.6%13.4%0.06n/a
Becton Dickinson & Co. BDX$57.7 billion63.803.9%9.6%-2.6%0.692.0%
Medline Inc. MDLN$52.2 billion57.614.9%5.7%n/a1.07n/a
GE HealthCare Technologies Inc. GEHC$37.2 billion17.3818.5%13.3%6.9%0.860.2%
Resmed Inc. RMD$33.1 billion21.4226.8%33.0%9.0%0.071.0%
Dexcom Inc. DXCM$29.6 billion31.1439.1%24.0%13.0%0.49n/a
Koninklijke Philips N.V. PHG *$29.2 billion29.228.2%8.0%-1.0%0.741.3%
West Pharmaceutical Services Inc. WST$27.9 billion44.8721.5%23.0%12.6%0.070.2%
Steris plc STE$24.5 billion29.9311.4%19.0%8.1%0.261.0%
Zimmer Biomet Holdings, Inc. ZBH$20.0 billion26.736.0%13.6%7.0%0.590.9%
Solventum Corp. SOLV$15.4 billion101.513.2%5.6%-2.8%1.05n/a
Smith & Nephew plc SNN *$13.7 billion21.7611.8%12.9%6.1%0.592.4%
Baxter International Inc. BAX$13.3 billionn/a-11.1%-1.9%5.3%1.322.0%
Glaukos Corp. GKOS$13.3 billionn/a-23.7%-25.5%46.9%0.00n/a
Penumbra Inc. PEN$12.6 billion80.459.9%12.1%17.0%0.00n/a
Cooper Companies, Inc. COO$11.9 billion21.296.8%12.8%4.7%0.31n/a
Align Technology Inc. ALGN$11.7 billion24.1711.4%14.9%4.4%0.00n/a
Insulet Corp. PODD$10.2 billion23.8727.2%18.4%26.5%0.61n/a
Globus Medical Inc. GMED$9.5 billion17.4511.6%21.6%13.4%0.00n/a
Bausch & Lomb Corp. BLCO$7.1 billionn/a-1.7%7.1%8.9%0.79n/a
MSA Safety Inc. MSA$6.6 billion21.8621.1%20.2%8.1%0.781.3%
Teleflex Inc. TFX$6.0 billion18.338.7%9.4%20.9%0.460.9%
Haemonetics Corp. HAE$5.5 billion53.8311.6%12.8%4.1%1.26n/a
Merit Medical Systems Inc. MMSI$5.2 billion32.809.2%13.5%9.1%0.42n/a
LivaNova plc LIVN$5.0 billion30.0114.3%10.7%11.7%0.22n/a
MiniMed Group, Inc. MMED$4.7 billionn/an/an/an/a0.00n/a
Heartflow, Inc. HTFL$4.5 billionn/a-42.3%-37.8%n/a0.00n/a
Integer Holdings Corp. ITGR$4.3 billion42.486.0%8.2%-0.3%0.71n/a
ICU Medical Inc. ICUI$4.3 billion71.992.8%5.1%-5.9%0.53n/a
Envista Holdings Corp. NVST$4.0 billion6.5120.5%25.4%9.8%0.46n/a
Pulse Biosciences, Inc. PLSE$3.9 billionn/a-45.6%-5,821.1%1,637.2%0.00n/a
Warby Parker Inc. WRBY$3.2 billion424.581.9%0.2%9.9%0.00n/a
TransMedics Group, Inc. TMDX$3.1 billion23.8926.2%11.9%28.5%0.930.0%
iRhythm Holdings, Inc. IRTC$3.0 billionn/a-21.8%-5.7%21.6%3.68n/a
Axogen, Inc. AXGN$3.0 billionn/a-6.4%-5.2%24.3%0.00n/a
AtriCure, Inc. ATRC$3.0 billion195.032.8%2.9%13.8%0.11n/a
UFP Technologies Inc. UFPT$2.3 billion30.9015.8%15.5%8.6%0.20n/a
Establishment Labs Holdings Inc. ESTA$2.0 billionn/a-246.6%-6.6%38.3%17.17n/a
Dentsply Sirona Inc. XRAY$1.9 billionn/a-8.9%-1.5%-1.4%1.626.8%
Lemaitre Vascular Inc. LMAT$1.9 billion29.4214.7%27.7%11.8%0.391.2%
Inspire Medical Systems, Inc. INSP$1.8 billion18.5712.2%1.8%-0.2%0.00n/a
Kestra Medical Technologies, Ltd. KMTS$1.7 billionn/a-67.4%-134.5%60.7%0.33n/a
Butterfly Network, Inc. BFLY$1.7 billionn/a-29.1%-46.9%39.3%0.000.0%
Enovis Corp. ENOV$1.6 billionn/a-35.3%-20.6%3.3%0.84n/a
NovoCure Ltd. NVCR$1.6 billionn/a-34.7%-17.2%12.9%0.56n/a
Conmed Corp. CNMD$1.5 billion21.306.9%9.9%1.6%0.771.2%
National Vision Holdings, Inc. EYE$1.4 billion29.335.6%4.1%7.8%0.26n/a
Cadre Holdings, Inc. CDRE$1.4 billion34.4211.2%10.7%18.3%1.011.2%
Staar Surgical Co. STAA$1.3 billion1,815,851,369,755,783,936.000.1%0.2%42.4%0.00n/a
Procept BioRobotics Corp. PRCT$1.2 billionn/a-34.9%-33.6%17.5%0.16n/a
Tandem Diabetes Care Inc. TNDM$1.2 billionn/a-36.4%-2.4%6.8%4.47n/a
Alphatec Holdings, Inc. ATEC$1.2 billionn/an/a-3.6%15.3%n/an/a
Iradimed Corp. IRMD$1.1 billion46.1422.5%32.3%11.0%0.000.9%
Si-Bone, Inc. SIBN$1.1 billionn/a-7.4%-7.6%14.0%0.190.0%
Integra LifeSciences Holdings Corp. IART$1.0 billion78.971.2%4.4%0.8%1.71n/a
Ceribell, Inc. CBLL$1.0 billionn/a-62.9%-69.8%31.3%0.17n/a
Artivion, Inc. AORT$986 millionn/a-3.9%2.3%14.0%0.81n/a
Bioventus Inc. BVS$893 million13.2523.8%9.7%3.9%0.96n/a
Beta Bionics, Inc. BBNX$855 millionn/a-20.7%-72.7%43.7%0.00n/a
Orthopediatrics Corp. KIDS$828 millionn/a-10.0%-9.4%16.1%0.31n/a
Tactile Systems Technology Inc. TCMD$585 million25.2610.5%9.4%14.4%0.00n/a
Sight Sciences, Inc. SGHT$558 millionn/a-57.8%-29.5%16.2%0.83n/a
Anteris Technologies Global Corp. AVR$553 millionn/a-41.2%-4,738.4%-9.6%0.00n/a
Delcath Systems, Inc. DCTH$517 million1,494.000.4%-1.9%35.8%0.00n/a
Avita Medical, Inc. RCEL$513 millionn/an/a-33.9%17.0%n/an/a
Angiodynamics Inc. ANGO$497 millionn/a-20.1%-11.2%8.2%0.00n/a
Mimedx Group, Inc. MDXG$482 millionn/a-9.1%-8.3%-22.8%0.00n/a
SS Innovations International, Inc. SSII$430 millionn/a-23.3%-15.8%89.7%0.00n/a
NeuroPace Inc. NPCE$428 millionn/a-160.9%-15.3%11.6%4.970.0%
Shoulder Innovations, Inc. SI$426 millionn/a-28.2%-54.4%n/a0.13n/a
Cerus Corp. CERS$407 millionn/a-9.7%-1.0%n/a0.84n/a
Carlsmed, Inc. CARL$395 millionn/a-43.1%-61.1%n/a0.18n/a
Mobia Medical, Inc. MOBI$372 millionn/an/an/an/a0.05n/a
Embecta Corp. EMBC$350 million4.18n/a21.9%-7.6%n/a7.4%
Orchestra BioMed Holdings, Inc. OBIO$341 millionn/a-305.5%-181.4%986.1%1.80n/a
Orthofix Medical Inc. OFIX$320 millionn/a-14.4%-4.7%3.0%0.52n/a
CapsoVision, Inc. CV$316 millionn/a-226.6%-217.1%n/a0.00n/a
Cytosorbents Corp. CTSO$308 millionn/an/a-34.7%3.1%n/an/a
Sanara MedTech Inc. SMTI$291 millionn/a-403.0%n/a12.9%5.85n/a
ClearPoint Neuro, Inc. CLPT$276 millionn/a-132.5%-70.6%32.5%1.86n/a
InfuSystem Holdings, Inc. INFU$272 million33.3414.4%9.3%2.5%0.35n/a
Treace Medical Concepts, Inc. TMCI$265 millionn/a-90.5%-24.4%-7.1%0.91n/a
Profound Medical Corp. PROF$264 millionn/a-76.4%-145.1%65.3%0.11n/a
Orasure Technologies Inc. OSUR$238 millionn/a-15.5%-48.1%-18.9%0.00n/a
Utah Medical Products Inc. UTMD$231 million22.138.6%28.4%-7.0%0.00n/a
Electromed, Inc. ELMD$226 million20.5820.9%18.8%15.3%0.00n/a
PRO DEX Inc. PDEX$202 million17.3524.4%16.8%13.3%0.33n/a
TriSalus Life Sciences, Inc. TLSI$200 millionn/a-430.7%-67.7%25.2%5.05n/a
Anika Therapeutics, Inc. ANIK$195 millionn/a-1.3%-2.1%9.4%0.00n/a
RxSight, Inc. RXST$190 millionn/a-20.9%-50.4%-14.3%0.00n/a
Inogen Inc. INGN$161 millionn/a-14.1%-8.7%3.2%0.00n/a
Edap TMS SA FOCL$158 millionn/a-104.3%-35.4%n/a0.99n/a
Koru Medical Systems, Inc. KRMD$143 millionn/a-10.1%-3.7%22.4%0.00n/a
Apyx Medical Corp. APYX$124 millionn/a-87.6%-5.5%24.4%3.89n/a
Pulmonx Corp. LUNG$112 millionn/a-124.4%-44.4%-3.2%1.11n/a
Stereotaxis, Inc. STXS$111 millionn/a-182.3%-75.7%-5.5%0.00n/a
SkinHealth Systems Inc. SKIN$102 millionn/a-32.8%2.4%-4.4%4.36n/a
Lakeland Industries Inc. LAKE$88 millionn/a-21.4%-4.1%-0.4%0.23n/a
Outset Medical, Inc. OM$79 millionn/a-85.4%-51.2%1.6%1.18n/a
Neuraxis, Inc. NRXS$77 millionn/a-114.0%-144.5%65.2%0.01n/a
Lucid Diagnostics Inc. LUCD$76 millionn/a-478.3%-930.8%24.9%2.15n/a
Lensar, Inc. LNSR$66 millionn/a232.8%-13.5%3.3%0.25n/a
NutriBand Inc. NTRB$66 millionn/a-130.7%-435.6%-37.3%0.00n/a
RenovoRx, Inc. RNXT$55 millionn/a-140.2%-489.0%n/a0.00n/a
PAVmed Inc. PAVM$10 millionn/a-34.5%-23,841.1%-89.0%0.43n/a
70 companies share its SEC industry code (Surgical & Medical Instruments & Apparatus); the rest are the names nearest in size in its wider industry, Medical Equipment, one of the Fama-French 48 industries, a published grouping of SEC industry codes.
Read moreBy market capitalisation; a click on a heading sorts by it, largest first, and a second click turns it round. Each figure is the same arithmetic as the ratio box above, on each company's own filings and latest close; a name marked * is a foreign company that files once a year, on its latest fiscal year.

The public record on DXCM

Dividendsno dividend in its filings for fiscal 2009 onward
Filings20 in twelve months: 12 current reports (8-K), about 5 results of operations; 5 officer or director change; 4 regulation FD disclosure; 2 other events; 1 shareholder vote
Planned insider sales29 Form 144 notices in twelve months, $13.0 million; latest 27 October 2026
Options tapeput/call 0.85 by open interest at the 6 November 2026 close; the straddle prices a 6.0% move to 13 November 2026
13F holders982 funds reported a position for the quarter to 30 June 2026; largest BlackRock, Inc.
Insider trading32 sales and 2 purchases on Form 4 in twelve months
Congress0 House trades disclosed in six months
Short interest15.7 million shares short, 4.75 days to cover at 15 October 2026
Documentsthe 10-K, the 10-Qs, the proxy and 5 earnings press releases, each linked

Filings

FilingPeriodFiledWhere
10-Q30 September 202629 October 2026EDGAR
10-Q30 June 202630 July 2026EDGAR
10-Q31 March 202630 April 2026EDGAR
10-K31 December 202512 February 2026EDGAR
10-Q30 September 202530 October 2025EDGAR
10-Q30 June 202530 July 2025EDGAR
10-Q31 March 20251 May 2025EDGAR
10-K31 December 202418 February 2025EDGAR
10-Q30 September 202424 October 2024EDGAR
10-Q30 June 202425 July 2024EDGAR

Reading about a stock somewhere else? Our free Chrome extension, GreekSoup Stock Ticker Lookup: Earnings, Insider Trades, 13F Holders, shows the latest quarter against a year ago, insider trades and 13F holders when you hover a $ticker such as $AAPL.